BR112017027985A2 - peptídeos terapêuticos e métodos de uso dos mesmos - Google Patents
peptídeos terapêuticos e métodos de uso dos mesmosInfo
- Publication number
- BR112017027985A2 BR112017027985A2 BR112017027985A BR112017027985A BR112017027985A2 BR 112017027985 A2 BR112017027985 A2 BR 112017027985A2 BR 112017027985 A BR112017027985 A BR 112017027985A BR 112017027985 A BR112017027985 A BR 112017027985A BR 112017027985 A2 BR112017027985 A2 BR 112017027985A2
- Authority
- BR
- Brazil
- Prior art keywords
- targeted
- peptides
- peptide
- directed
- brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Insects & Arthropods (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
Abstract
a presente invenção refere-se aos peptídeos que são endereçados, se distribuem, se direcionam, são direcionados a ou se acumulam em tumores, cânceres ou células doentes. peptídeos que atravessam a barreira sangue-cérebro e são endereçados, se distribuem, se direcionam, são direcionados a ou se acumulam no cérebro e em uma região específica do cérebro são também divulgados. composições farmacêuticas e usos para os peptídeos ou complexos de peptídeo-agente ativo que compreendem tais peptídeos são adicionalmente divulgados. tais composições podem ser formuladas para entrega direcionada ou não direcionada de um fármaco a uma região, tecido, estrutura ou célula-alvo. as composições direcionadas da invenção podem entregar peptídeo ou complexos de peptídeo-agente ativo a regiões, tecidos, estruturas ou células-alvo direcionadas pelo peptídeo.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185527P | 2015-06-26 | 2015-06-26 | |
US201562185529P | 2015-06-26 | 2015-06-26 | |
US201562239743P | 2015-10-09 | 2015-10-09 | |
US201562239739P | 2015-10-09 | 2015-10-09 | |
US201662322724P | 2016-04-14 | 2016-04-14 | |
US201662354642P | 2016-06-24 | 2016-06-24 | |
PCT/US2016/039431 WO2016210376A2 (en) | 2015-06-26 | 2016-06-24 | Therapeutic peptides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017027985A2 true BR112017027985A2 (pt) | 2018-08-28 |
Family
ID=57586477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017027985A BR112017027985A2 (pt) | 2015-06-26 | 2016-06-24 | peptídeos terapêuticos e métodos de uso dos mesmos |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180371033A1 (pt) |
JP (1) | JP2018521994A (pt) |
AU (1) | AU2016283391A1 (pt) |
BR (1) | BR112017027985A2 (pt) |
CA (1) | CA2987636A1 (pt) |
IL (1) | IL256515A (pt) |
WO (1) | WO2016210376A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
JP6966424B2 (ja) * | 2015-09-09 | 2021-11-17 | フレッド ハッチンソン キャンサー リサーチ センター | 軟骨ホーミングペプチド |
EP3571215A4 (en) | 2017-01-18 | 2020-12-30 | Fred Hutchinson Cancer Research Center | PEPTIDE COMPOSITIONS AND METHOD OF USE THEREOF TO INTERRUPT TEAD INTERACTIONS |
EP3595699A4 (en) * | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | CARTILLE HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
CN107286231A (zh) * | 2017-05-18 | 2017-10-24 | 长沙沁才生物科技有限公司 | 一种动物来源活性多肽spgp‑v |
US11331393B2 (en) | 2017-06-15 | 2022-05-17 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE |
CN111744020A (zh) * | 2019-03-27 | 2020-10-09 | 中国科学院宁波材料技术与工程研究所 | 一种主动靶向响应型多肽药物、其制备方法和应用 |
CA3138933A1 (en) * | 2019-05-22 | 2020-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Drug conjugates and methods of using same |
EP4048786A1 (en) * | 2019-10-22 | 2022-08-31 | Genethon | Chimeric polypeptides and uses thereof |
WO2023107428A1 (en) * | 2021-12-07 | 2023-06-15 | The Regents Of The University Of California | Methods for treating traumatic brain injury |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
CA2788824C (en) * | 2010-02-04 | 2019-03-12 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN103097403B (zh) * | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
CN105189540A (zh) * | 2012-12-10 | 2015-12-23 | 弗莱德哈钦森癌症研究中心 | 含脂质运载蛋白融合伴侣 |
-
2016
- 2016-06-24 AU AU2016283391A patent/AU2016283391A1/en not_active Abandoned
- 2016-06-24 WO PCT/US2016/039431 patent/WO2016210376A2/en active Application Filing
- 2016-06-24 BR BR112017027985A patent/BR112017027985A2/pt not_active Application Discontinuation
- 2016-06-24 CA CA2987636A patent/CA2987636A1/en not_active Abandoned
- 2016-06-24 US US15/739,669 patent/US20180371033A1/en not_active Abandoned
- 2016-06-24 JP JP2017566104A patent/JP2018521994A/ja active Pending
-
2017
- 2017-12-24 IL IL256515A patent/IL256515A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016210376A3 (en) | 2017-03-02 |
AU2016283391A1 (en) | 2017-11-30 |
JP2018521994A (ja) | 2018-08-09 |
US20180371033A1 (en) | 2018-12-27 |
CA2987636A1 (en) | 2016-12-29 |
WO2016210376A2 (en) | 2016-12-29 |
IL256515A (en) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
CY1122771T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων | |
CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
ZA202002094B (en) | Trispecific proteins and methods of use | |
BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
BR112018006489A2 (pt) | composições e métodos para inibir a expressão gênica de lpa | |
BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
BR112018004078A2 (pt) | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo | |
BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
BR112019024747A2 (pt) | formulações de dose fixa | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
BR112015021222A2 (pt) | inibidores de ras e usos dos mesmos | |
BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
BR112017025698A2 (pt) | composições e métodos para inibir a expressão do gene de hif2alfa | |
BR112019001945A2 (pt) | composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto | |
BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
WO2018081726A3 (en) | Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis | |
BR112016016202A2 (pt) | Construtos de direcionamento de receptores e uso dos mesmos | |
BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |